Direct Evidence of Internalization of Tau by Microglia in Vitro and in Vivo by Bolós, Marta et al.




Direct Evidence of Internalization of Tau
by Microglia In Vitro and In Vivo
Marta Bolo´sa,b,1, Marı´a Llorens-Martı´na,b,1, Jero´nimo Jurado-Arjonaa,b, Fe´lix Herna´ndeza,b,
Alberto Ra´banoc and Jesu´s Avilaa,b,∗
aCentro de Investigacio´n Biome´dica en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
bCentro de Biologı´a Molecular “Severo Ochoa” CSIC-UAM, Madrid, Spain
cNeuropathology Department, CIEN Foundation, Madrid, Spain
Accepted 8 October 2015
Abstract. The microtubule-associated protein (MAP) tau plays a critical role in the pathogenesis of tauopathies. Excess tau can
be released into the extracellular medium in a physiological or pathological manner to be internalized by surrounding neurons—
a process that contributes to the spread of this protein throughout the brain. Such spreading may correlate with the progression of
the abovementioned diseases. In addition to neurons, tau can be internalized into other cells. Here we demonstrate that microglia
take up tau in vitro and in vivo. In this regard, microglia from primary cultures internalized soluble (human recombinant tau42)
and insoluble (homogenates derived from human AD brain) tau in vitro. Furthermore, using stereotaxic injection of tau in mice
in vivo, we show that murine microglia internalize human tau. In addition, we demonstrate, for the first time, that microglia
colocalize with various forms of tau in postmortem brain tissue of patients with Alzheimer’s disease and non-demented control
subjects. Our data reveal a potential role of microglia in the internalization of tau that might be relevant for the design of strategies
to enhance the clearance of extracellular tau in neurodegenerative diseases characterized by the accumulation of this protein.
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INTRODUCTION
Tau is a microtubule-associated protein that is toxic
when present (mainly in its phosphorylated form)
in high amounts inside neurons. In tauopathies, like
Alzheimer’s disease (AD), intracellular aggregates of
phosphorylated tau are released to the extracellular
space and propagate following a stereotypical pattern,
from the transentorhinal and entorhinal cortex to the
hippocampal formation and eventually to the neocor-
tex. The spread of tau may contribute to cognitive
decline in age-associated tauopathy [1, 2]. In 2006, the
notion of extracellular toxic tau protein was proposed
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[3]. Extracellular tau has also been detected in the
brain interstitial fluid of both wild-type and P301S
tau-overexpressing mice in microdialysis studies [4].
In addition, the levels of cerebrospinal fluid tau are
elevated in AD, as is also the case in patients with
severe traumatic brain injury [5, 6]. Tauopathies are
characterized by massive accumulation of extracellular
tau, mainly in an aggregated form. Studies performed
in animals and in cell culture [7–11] suggest that tau
aggregation propagates from neuron to neuron [8, 12].
Furthermore, it has been suggested that tau is
secreted physiologically. Indeed, its physiological
release was postulated as a way to prevent the toxicity
caused by elevated intracellular tau [13, 14].
Microglia cells are the resident macrophages that
constitute the main active immune cells in the brain.
These cells play a continuous role of surveillance and
phagocytosis in the central nervous system (CNS) and
provide the initial response to CNS damage. Increasing
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evidence supports the notion that microglia-mediated
neuroinflammatory processes directly contribute to the
pathogenesis of AD. In this regard, neuroinflammation
has been implicated in driving the hyperphosphory-
lation and aggregation of tau and neurodegeneration
and recently in various models of tauopathies [15–23].
Nevertheless, it is unknown whether brain inflamma-
tion in AD patients is the cause of the disease or a
secondary phenomenon.
Microglia colocalize with amyloid plaques in AD
brains. It is been demonstrated that microglia are one of
the major determinants of brain amyloid- (A) clear-
ance and amyloid burden [24, 25]. In AD, microglia
are able to bind to soluble A oligomers and A
fibrils via cell surface receptors, including SCARA1,
CD36, CD14, 61 integrin, CD47, and Toll-like
receptors, and this process is thought to be part of
the inflammatory reaction in AD [26, 27]. Generally,
microglia are believed to clear A at early stages of
AD, but as the disease progresses, the ability of phago-
cytosis decreases due to reduced expression of their
A-binding receptors and A-degrading enzymes.
However, microglia maintain their ability to produce
proinflammatory cytokines induced by soluble A
or A deposits [28, 29]. Although the relationship
between microglia and A clearance is well estab-
lished, little is known about the contribution of these
cells to the uptake/clearance of extracellular tau. Of
note, therapeutic interventions that prevent the uptake
of aggregate seeds into neurons or promote microglial
clearance may arrest disease. It has recently been
reported that microglia enhance the clearance of aggre-
gated tau when passive immunization with an anti-tau
monoclonal antibody is used in vitro [30, 31].
Here we analyzed human tau in the following three
systems: microglia cell cultures exposed to human
tau; mice subjected to stereotaxic injection of tau;
and brain tissue obtained from AD patients and con-
trol subjects. Using primary cultures of microglia
and mice, respectively, we unambiguously demon-
strate that microglia internalize extracellular soluble
and insoluble tau in vitro and in vivo. Furthermore,
we demonstrate that microglia colocalize with neu-




The recombinant human tau isoform containing 2
N-terminal inserts and 4 microtubule binding repeats
(tau42: [32]) was isolated as described previously [33].
Briefly, the proteins isolated were characterized by gel
electrophoresis, followed by staining with Coomassie
blue. Purified tau was labeled with sulfoindocyanine
Cy5 dye (GE Healthcare, UK), as described previously
[34] following the manufacturers recommendations.
Briefly, 1 ml of recombinant tau protein (2 mg/ml) was
mixed with a sample of Cy5 dye at room temperature
for 1 h for coupling to fluorophore. To remove the
excess of free dye, the mixture was dialyzed overnight
at 4◦C against PBS and filtrated through a Sephadex G-
50 column. Cy5-coupled tau protein was characterized
by Western blotting with an antibody that recognizes
the dye (GE Healthcare, UK). The Cy5 fluorescent
tracer was used because, due to its autofluorescence
characteristics, the internalization of labeled-tau42
into the microglia is easier to follow than if other tags
were used.
Primary microglia culture
Cerebral cortices from 2-day-old Wistar rats were
dissected, stripped of meninges, and digested with
0.1% trypsin at 37◦C in HBSS (Gibco, USA) medium
for 10 min. Trypsinization was stopped by the addi-
tion of DMEM/Glutamax 1%/Pyruvate 1% (Gibco,
USA) culture medium supplemented with 10% fetal
bovine serum (Gibco, USA), 100 U/mL penicillin, and
0.1 mg/mL streptomycin (Gibco, USA). The cell sus-
pension was pelleted, resuspended in culture medium,
and finally suspended into a single-cell suspension by
repeated pipetting, followed by passage through a 40-
m pore mesh. Cells were seeded into a 75-ml flask
and cultured in medium at 37◦C in humidified 5%
CO2–95% air. The culture medium was changed after
3 days. Floating microglia were recovered after 10–12
days by mild shaking and centrifugation and then
were seeded onto 24-well plates (3×104 cells/well)
with coverslips. Adherent cells were incubated for
48 h before being used for the experiments. Serum-free
medium was used for the experiments. Cell specificity
was determined using the microglial marker Iba-1, a
polyclonal antibody (1:1000, Innogenetics, Belgium),
and the astroglial marker GFAP (1:2000, Promega,
USA). Cultured primary microglia were more than
98% positive for Iba-1.
Tau internalization by microglia
For the soluble tau experiments, primary microglia
were treated with tau-Cy5 or vehicle (phosphate
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saline buffer (PBS)-Cy5) at 1M for a range of times
(5 min, 15 min, 1 h, and 6 h). In the case of insoluble
tau, cells were treated with homogenized AD brain
(tau-agg) or control PBS, following the same protocol.
After treatment, cells were washed three times with
PBS in order to remove the tau bound to the mem-
brane. Cells were fixed with 4% paraformaldehyde
in phosphate buffer for the immunofluorescence
analysis. Each time-point was performed three times
and the entire experiment was repeated independently
three times (n = 3). A total of 50 cells per time
were analyzed.
Immunocytochemistry
After treatment, cells were fixed in 4% (w/v)
paraformaldehyde in PBS. They were then stained
with rabbit or goat anti-Iba1 (1:1000, Wako),
rabbit anti-GFAP (1:2000, Promega), mouse anti-
Cy5(1:2000, GE Healthcare), and rabbit anti-tau
(1:1000, Novus, USA), all used diluted in 1% (v/v)
bovine serum plus 1% (v/v) triton in PBS. They were
then incubated with a donkey anti-goat IgG conjugated
to Alexa Fluor 488, donkey anti-rabbit IgG conjugated
to Alexa Fluor 488 or 555, donkey anti-mouse IgG
conjugated to Alexa Fluor 647 (1:1000 diluted in 10%
(v/v) bovine serum plus 1% (v/v) triton in PBS) and
DAPI at 1:10,000 dilution. Iba-1, Cy5, and DAPI-
labeled cells were counted under a 40× objective in
five random fields throughout the coverslips. Confocal
stacks of images were obtained (Z-axis interval:
1m), and z-projections were analyzed to determine
the colocalization of Iba-1 and Cy5. Using ImageJ, we
analyzed total internalized tau in thresholded images
(threshold value = 50; 255) as the percentage of Cy5
fluorescence intensity inside the cell normalized to that
of total Iba1. For the statistical analysis, the total inter-
nalized Cy5-tau was related to the internalized Cy5
(control) at each time-point. A total of 50 cells per time
were analyzed.
Animals
2-month-old C57Bl/6 (Harlan Laboratories,
Netherlands) mice were used for the in vivo exper-
iments involving stereotaxic injection of tau. Mice
were housed in a specific pathogen-free colony
facility, in accordance with European Community
Guidelines (directive 86/609/EEC), and handled
following European and local animal care proto-
cols. Animal experiments received the approval of
the CBMSO’s Ethics Committee. Four mice per
experimental condition were used. Mice were left
undisturbed for two weeks after arrival. Animals were
10 weeks old when the stereotaxic injections were
performed.
Stereotaxic surgery and sacriﬁce
Mice were anesthetized with Isoflouran and placed
in a stereotaxic frame. Coordinates (mm) relative to
the Bregma in the anteroposterior, mediolateral, and
dorsoventral planes were as follows: dentate gyrus
(DG) [–2.0, 1.4, 2.2]. 2l/DG of tau-Cy5 or tau-
aggregate (tau-agg) solution was infused at 0.2l/min
via a glass micropipette. After one week, mice were
fully anesthetized by means of an intraperitoneal injec-
tion of pentobarbital and transcardially perfused with
saline followed by 4% paraformaldehyde in phos-
phate buffer (PB). Brains were removed and post-fixed
overnight.
Human subjects
The use of human hippocampus brain tissue samples
was coordinated by local Brain Bank (Banco de Tejidos
CIEN, Madrid), following national laws and interna-
tional ethical and technical guidelines on the use of
human samples for biomedical research purposes. In
all cases, brain tissue donation, processing, and use for
research were in compliance with published protocols
(Best Practices for Repositories [35]), which include
informed consent for brain tissue donation from living
donors and the approval of the whole donation process
by an ethical committee.
Preparation of brain tissue extracts
Brain extracts were isolated by homogenizing the
tissue in ice-cold buffer (1:10 w/v) consisting of
20 mM HEPES pH7.4, 100 mM NaCl, 50 mM NaF,
5 mM EDTA, 1% Triton X-100, and protease inhibitors
(Roche, Switzerland), plus 100× ortovanadate and
1/1000 okadaic acid (Sigma-Aldrich, USA). The
homogenate was centrifuged at 100,000× g for 30 min,
and the supernatant was stored at –20◦C until use.
Immunohistochemistry and confocal analysis
Sagittal brain sections were obtained on a Leica
VT1200S vibratome (50-m thick sections). Immuno-
histochemistry was performed as described previously
[36]. For all the immunohistochemical analyses, series
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of brain slices were made up randomly of one section
from every ninth. One series, containing 8–10 sec-
tions, was used for the immunohistochemical detection
of Iba1 and tau. In human tissue, the following pri-
mary antibodies were used: mouse anti-phospho-tau
(PHF-1 epitope) (1:250, kindly provided by Davis);
mouse anti-phospho-tau (AT100) (1:100, Innogenet-
ics); mouse anti-phospho-tau (AT180) (1:100, Inno-
genetics); rabbit anti-phospho-tau (Tau396) (1:500,
Life Technologies, USA); rabbit anti-phospho-tau
(Tau404) (1:500, Life Technologies); mouse anti-
dephosphorylated tau (Tau1) (1:200, Chemicon,
Massachusetts); mouse anti-human tau (HT7) (1:500,
Thermo Scientific, Waltham, MA); mouse anti-
phospho-au (AT8) (1:100, Innogenetis); and goat anti-
Iba1(1:500, Wako), all in 1% (v/v) bovine serum plus
1% (v/v) triton in PB 1N. In mice, the following anti-
bodies were used: mouse anti-human tau (HT7) (1:500,
Thermo Scientific, MA); mouse anti-Cy5 (1:2000, GE
Healthcare); and goat anti-Iba1 (1:500, Wako), all in
1% (v/v) bovine serum plus 1% (v/v) triton in PB 1N.
All primary antibodies were incubated for 48 h at 4◦C.
The following secondary Alexa-conjugated antibodies
were used at a final concentration of 1:1,000 diluted
in 1% (v/v) bovine serum plus 1% (v/v) triton in PB
1N: donkey anti-mouse IgG conjugated to Alexa Fluor
555; donkey anti-rabbit IgG conjugated to Alexa Fluor
555; and donkey anti-goat IgG conjugated to Alexa
Fluor 647 (Life Technologies). Secondary antibodies
were incubated overnight at 4◦C. All sections were
counterstained with DAPI (Calbiochem, 1:5000). For
human slices, immunohistochemistry was performed
as described, adding an autofluorescence eliminator
reagent (Millipore, USA) after DAPI incubation in
order to remove possible autofluorescence of the tis-
sue. Images were taken under 25X, 40X, and 63X
objectives. Confocal stacks of images were obtained
(Z-axis interval: 1m), and z-projections were ana-
lyzed to determine the colocalization of the Iba-1 and
tau stained.
Statistical analysis
Statistical analysis was performed with GraphPad
Prism software, Version 5.01. Data were tested by two-
way ANOVA. Post-hoc comparisons were analyzed
using Tukey’s test. Differences were considered sta-
tistically significant when the probability, p, of the
null hypothesis was ≤0.05. Data are presented as the
means ± S.E. All results were obtained in at least three
independent experiments.
RESULTS
Microglia take up soluble and insoluble human tau
in vitro
It has been suggested that sarkosyl-insoluble tau
is internalized by microglia [31]. To confirm these
results, we used a primary microglia culture model
and insoluble tau obtained from homogenates of post-
mortem AD brain tissue (tau-agg). As microglia do
not have endogenous tau, the tau antibody used (rabbit
anti-human tau) recognized only the exogenous form
of the protein taken up by microglia. Microglia were
incubated with tau-agg or control PBS. Representative
z-stack and orthogonal view images of treated cells are
shown in Fig. 1A–C. Tau (red) was not present inside
Iba1-stained microglia cells (green) when these were
treated with control PBS (Fig. 1A). However, when
tau-agg was added to the culture medium, tau was
detected as red puncta inside microglia (Fig. 1B,C).
These results are consistent with the findings of pre-
vious studies [31], confirming that microglia derived
from primary cultures have the capacity to take up
insoluble tau.
To study whether soluble tau was also internalized
by microglia, tau42 labeled with Cy5 (tau-Cy5), defi-
cient in the formation of tau aggregates, or control
PBS-Cy5 was added to primary microglia cultures at
1M of final concentration (Fig. 1D,E). Tau (stained
using an antibody against Cy5) was detected inside
the microglia treated with tau-Cy5 (Fig. 1E) but not
in the control (Fig. 1D). This observation indicates the
absence of an effect of Cy5 on tau uptake.
Next, we examined whether the internalization of
tau by microglia was time-dependent. Microglia were
incubated with tau-Cy5 or control PBS-Cy5 for 0, 5,
15, 60, and 360 min. After this time, we calculated the
presence of internalized tau as the difference between
the percentage of total Iba1 fluorescence intensity and
the percentage of Cy5 fluorescence intensity inside the
cell compared to the control (Fig. 1K). Representative
orthogonal images for the different time points showed
that tau colocalized with Iba1 (Fig. 1F–J). We found
that as early as 5 min after treatment, tau was detected
inside microglia and the Cy5 fluorescence intensity
progressively increased during the incubation time, up
to the last time point of 360 min. After 6 h of treat-
ment with tau-Cy5, but not with control PBS-Cy5, we
detected a high mortality of microglia. This observa-
tion could be attributed to a toxic effect of tau on these
cells. We were therefore not able to quantified cells
in the further times and consequently set 6 h as the
M. Bolo´s et al. / Tau Uptake by Microglia 81
Fig. 1. Microglia internalized extracellular tau in vitro. Microglia derived from primary cultures were incubated with insoluble tau-agg (A–C)
or soluble tau-Cy5 (D–K). Panels A–C show representative immunofluorescence images of microglia stained for Iba1 (green) and tau (red). The
cultures were either untreated (A) or treated with 1M tau-agg (B,C). Panels D and E show representative images of microglia culture control
(D) or treated with 1M tau-Cy5. Immunofluorescence images for Iba1 (green), Cy5 (red), and DAPI are shown separately. Panels F–J show
representative immunofluorescence images of microglia (Iba1, green) treated with 1M tau-Cy5 (Cy5, red) for different times (0–360 min). K)
Quantification of results from immunofluorescence analysis showing % Cy5/Iba1 fluorescence intensity present in cells treated with tau-Cy5
relative to the control Cy5. Bars show means ± S.E. ∗∗∗p≤ 0.001. Orange scale bar: 10m, White scale bar: 50m.
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Fig. 2. Murine microglia internalized human tau in vivo. Representative images showing microglia labeled with Iba1 (white), human tau
labeled with anti-Cy5 antibody, an anti-human tau antibody (HT7) (red), and DAPI (blue) in tissue derived from C57Bl/6J mice stereotaxically
injected with PBS-Cy5 (A–D) and 1M of tau-Cy5 (E–H) or tau-agg (I–L). B and F) Tile Scan acquisition showing the whole anatomy of
the hippocampus in control (B) or tau-Cy5-injected (F) mice. A,E,I,J representative images show DG hippocampal region injected with control
PBS-Cy5 (A), tau-Cy5 (E), or tau-agg (I) and its magnification (J). C,D,G,H,K and L show high-power magnifications of the CA3 hippocampal
region. One week after injection, it can be observed Iba1 (white) colocalization with both Cy5 (G) and HT7 (K), but not with PBS-Cy5 (C), in
the hippocampus and the magnification images of PBS-Cy5 (D), tau-Cy5 (H) and tau-agg (L). DG, dentate gyrus. GL, granular layer. Yellow
triangles indicate the presence of microglia and tau colocalization. Magenta scale bar: 10m. Green scale bar: 50m. Red scale bar: 200m.
Fig. 3. Microglia and tau colocalization in human AD brain tissue. Representative images showing microglia labeled with Iba1 (white), and
tau labeled with different anti-human tau antibodies (red) and DAPI (blue) in tissue derived from the brains of a human AD patient (A–I)
and a control subject (J–O). In order to analyze the colocalization of Iba1 and Tau staining, orthogonal views have been provided for each
Z-projection at the right and bottom of each photomicrograph. It should be noted that the orthogonal views correspond to one single plane. It
is possible to observe colocalization of the red and white channels indicated by the intersections between yellow. Various tau antibodies were
used to detect tau in AD brain: anti-phospho-tau (PHF-1 epitope) in panel A and its magnification in B; anti-phospho-tau (AT100) in panel C;
anti-phospho-tau (AT180) in panel F; anti- phospho-tau (Tau396) in panel D and its magnification in E; anti- phospho-tau (Tau404) in panel G;
anti-de-phosphorylated tau (Tau1) in panel H; and anti-total human tau (HT7) in panel I. In control brains, representative images of the following
anti-human tau antibodies are shown: anti- phospho-tau (AT180) in panel J; anti- phospho-tau (AT8) in panel K; anti-phospho-tau (Tau396) in
panel L, and anti- phospho-tau (Tau404) in panels M–O. It can be observed how aberrant tau-labeled structures are much more abundant in the
brain of the AD patient than in that of the control subject. It should be noted that independently of the phosphorylation state of tau, microglia
show close contact with tau-labeled structures, thus suggesting that these cells play an active surveillance role aimed to control the progression
of these aberrant structures. Green asterisks indicate the presence of tangles. Yellow triangles indicate microglia and tangle colocalization. Blue
scale bar: 10m. Green scale bar: 50m.
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last experimental time point for our tau internalization
study.
Extracellular human tau was internalized by
microglia in vivo
As our results suggested that extracellular tau was
internalized by microglia in primary cultures, we next
examined whether murine microglia takes up human
tau in vivo. With this aim, both control PBS-Cy5
(Fig. 2A–D) and soluble tau (tau-Cy5) (Fig. 2E–H)
were injected into the brains of C57Bl/6 mice. After
one week, hippocampal brain slices were examined. A
panoramic view showing the pattern of staining with an
anti Cy5 antibody after the injections can be observed
in control (Fig. 2B) and tau-Cy5 injected (Fig. 2F)
mice. When soluble tau was injected (Fig. 2E–H),
Iba1-labeled microglia (white) colocalized with Cy5-
labeled tau (red), in the dentate gyrus (Fig. 2E) and
CA3 (Fig. 2G,H) hippocampal fields. Note in the
high-power magnification of this image (Fig. 2E,G,H),
marked with yellow triangles, that the colocalization
between Iba1+ and Cy5+ occurred in all the Iba1+
cells in the area. Orthogonal view of the magnifica-
tion image showed how tau clearly colocalized with
microglia (Fig. 2H). Thus, we concluded that microglia
have the capacity to internalize soluble human tau
in vivo.
In addition, we injected insoluble tau form (tau-agg)
following the same protocol. The presence of tau was
detected with the HT7 anti-human tau antibody (red).
Intense staining of HT7 inside the Iba1+ microglia
(white) was detected in the dentate gyrus (Fig. 2I,J)
and CA3 (Fig. 2K,L) hippocampal subfields. These
results showed, for the first time, that mouse microglia
efficiently recognize and internalize free tau in vivo
regardless of whether it is present in its soluble or
insoluble form.
Microglia colocalized with tau in human brain
One of the hallmarks of AD are NFTs, which
comprise aggregates of hyperphosphorylated tau.
Although the presence of microgliosis in AD is well
known, no study has demonstrated that microglia is
in direct apposition of tau in human tissue. To address
this question, we next examined whether microglia
colocalize with tau in postmortem tissue derived from
human AD and control brains and studied the three-
dimensional organization of these putative contacts.
Tau was detected using several antibodies. Indepen-
dently of the phosphorylation state of the protein, all
these antibodies distinguished tau accurately in the
two types of brain tissue. Nevertheless, the presence of
tau was more accentuated in the AD brain (Fig. 3A–I
versus Fig. 3J–O). In line with this, various antibodies
against phosphorylated tau showed high levels of
phospho-tau in tissue derived from human AD brain:
anti-PHF1 (Fig. 3A,B), anti-Tau396 (Fig. 3D,E),
anti-AT100 (Fig. 3C), anti-AT180 (Fig. 3F), and
anti-Tau404 (Fig. 3G). Interestingly, low levels of
phospho-tau were also detected in tissue derived from
human control brain: anti-AT180 (Fig. 3J), anti-AT8
(Fig. 3K), anti-Tau396 (Fig. 3L), and anti-Tau404
(Fig. 3M–O). We found that tangles, marked with
green asterisks, were labeled with all of the anti-
bodies used. Accordingly, more tangles were present
in the AD brain as compared to control subjects.
Furthermore, these tangles and other tau+ structures
were found under close surveillance by Iba1-labeled
microglia cells (Fig. 3A–O). We observed direct appo-
sition of microglia to different types of tau+ structures,
including NFTs and dystrophic neurites. Microglia
and aberrant tau+ structures were found to be in close
contact (yellow triangles in Fig. 3A,C,D,F,G). In tissue
derived from control brain, scattered tangles were
found in some hippocampal regions. In these areas,
microglia (white) also colocalized with tangles (red).
Green asterisks indicate the direct overlay between
microglia and these tau+ NFT (yellow triangles)
(Fig. 3J–O). In addition, microglia colocalized not
only with phosphorylated forms of tau, but also in
those cases in which a total human-tau (HT7) antibody
was used (Fig. 3I), and, importantly, they also showed
a marked colocalization with de-phosphorylated forms
of the protein, stained with an anti-Tau1 antibody
(Fig. 3H). In summary, these results demonstrate that
microglia colocalized with tau in human tissue of both
AD patients and control subjects. On the basis of our
observations, we propose that the surveillance role
of microglia is driven by the presence of tau protein
in aberrant structures such as NFTs and dystrophic
neurites.
DISCUSSION
The present study shows that human extracellular
tau is internalized by microglia in vitro and in vivo.
We tested this internalization in three models, namely
primary microglia culture exposed to tau as the in vitro
model, C57Bl/6 mice stereotaxically injected with
tau, and human tissues from AD patients and control
subjects for the in vivo studies. Soluble (monomeric or
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small aggregates) and insoluble (aggregates) human
tau were used. Both forms of the protein were inter-
nalized by microglia derived from primary cultures.
After intracerebral injection of tau in C57Bl/6 mice,
the two forms of the protein were also internalized
by microglia. Furthermore, different forms of tau
present in tissue derived from the postmortem brains
of human AD patient and control subject colocalized
with microglia. Taken together, these results demon-
strate that microglia take up tau, regardless of the
aggregation state of the protein, thereby supporting the
notion that these cells play a key role in the clearance
of tau.
A number of studies showing the release of extra-
cellular tau by cell lines and neurons via multiple
pathways, including cell death, strongly support the
hypothesis that the secretion of tau is an important
biological function of the protein, especially in dis-
ease [37, 38]. In addition, increased intracellular levels
of phosphorylated tau could be detrimental and would
thus support the notion that secretion is a mechanism
by which excess tau, mainly in the form of aggregates,
is removed, thereby preventing the toxicity cause by
its accumulation. This source of extracellular tau can
be internalized by other cells, including neurons [39].
The spread of tau from cell to cell has been proposed to
be one of the mechanisms underlying the progression
of tau pathologies [12, 40, 41].
Therefore the inhibition of tau uptake by other cells
or increasing microglial clearance of extracellular tau
could be useful strategies to arrest these pathologies.
In addition, genome-wide association studies have
recently found risk factors associated with a higher
probability of developing sporadic AD. Two of these
genes are TREM2 and CD33 [42–44], which are
involved in the phagocytic and degradative functions
of microglia. These genes play a key role in A clear-
ance by microglia [24, 45], a process that prevents the
formation of amyloid plaques in AD. These findings
suggest that microglial phagocytosis could be impaired
in tauopathies, like AD, thus contributing to the pro-
gression of the disease. In addition, recent evidence
suggests that microglia participate in the internaliza-
tion and degradation of pathological tau (insoluble)
in vitro [30] and ex vivo [31], although the precise
mechanisms remain unclear.
In primary cultures of microglia, we confirmed that
extracellular insoluble human tau is internalized. These
results are consistent with the findings of previous stud-
ies. Nevertheless, the most novel finding of the present
work is that that primary cultures of microglia also
take up soluble tau. Although soluble tau is consid-
ered to be non-toxic, we observed high mortality of
microglia that took up tau during a 6-h treatment. This
observation could be attributable to a loss of the pro-
teostasis of the cell. The role played by microglia in
the uptake of tau was confirmed by in vivo studies.
Therefore, the colocalization of Iba1+ microglia and
stereotaxically-injected tau was analyzed in the hip-
pocampus of C57BL/6 one week after the injection.
Coincident with the in vitro results, we found that the
microglia present in the hippocampus colocalizes with
tau-Cy5 (detected with an anti-Cy5 antibody) as well
as with tau-agg (detected with an anti-human tau anti-
body (HT7)). In addition and as expected, we found
that the presence of tau (tangles and other aberrant
structures) was enormously increased in human AD
brains compared to the control subjects. Again, we
observed microglia colocalizing with tau. Microglia
were in close contact with aberrant structures in both
AD patients and control subjects. These data strongly
suggest that microglia play a crucial role in the surveil-
lance of the aberrant process of NFT formation and in
tau clearance under both physiological and pathologi-
cal conditions.
In summary, using in vitro and in vivo models,
here we demonstrate that microglia take up tau inde-
pendently of the aggregation state of the protein. In
addition, we show, for the first time, that microglia
internalize extracellular tau in murine and human
in vivo models. All together these results point to these
cells as potential therapeutic targets in tauopathies.
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